View Older Stories View More Recent Stories

Oct 17, 2022 07:31AM Biogen (BIIB) Announces FDA’s 3-Month Extension of Review Period for NDA for Tofersen
Oct 17, 2022 07:30AM Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Oct 17, 2022 07:30AM Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Oct 17, 2022 06:33AM SAGE (SAGE) and Biogen (BIIB) Report Further Analyses from Phase 3 Study of Zuranolone
Oct 17, 2022 06:30AM Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Oct 13, 2022 09:00AM GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®
Oct 3, 2022 08:00AM Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Oct 3, 2022 08:00AM Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Sep 30, 2022 07:00AM Biogen (BIIB) Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA
Sep 30, 2022 07:00AM Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
Sep 30, 2022 07:00AM Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
Sep 28, 2022 07:00AM Eisai, Biogen (BIIB) Announce Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint for Reduction of Early Alzheimer's Disease
Sep 27, 2022 07:30PM LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH E
Sep 21, 2022 05:15PM The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
Sep 21, 2022 05:15PM The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
Sep 19, 2022 06:30AM Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
Sep 8, 2022 06:20AM Biogen (BIIB) Announce NEJM Publishes Second Manuscript Reporting Positive Phase 2 Results for Litifilimab in Lupus
Sep 7, 2022 05:45PM The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
Sep 7, 2022 05:45PM The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
Aug 3, 2022 07:32PM EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENC
Jul 28, 2022 07:30AM Biogen (BIIB) Reports Publication of Positive Phase 2 Data on Litifilimab
Jul 28, 2022 07:30AM The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Jul 28, 2022 07:30AM The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Jul 26, 2022 07:31AM Biogen (BIIB) Announces FDA Accepted NDA, Granted Priority Review of Tofersen for a Rare, Genetic Form of ALS
Jul 26, 2022 07:30AM Biogen (BIIB) Announces FDA Accepts NDA and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Jul 26, 2022 07:30AM FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Jul 26, 2022 07:30AM FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Jul 5, 2022 07:30PM THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Jun 22, 2022 09:00AM Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
Jun 21, 2022 06:37AM European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)
Jun 15, 2022 07:32AM Biogen (BIIB) Announces New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA
Jun 15, 2022 07:30AM New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
Jun 15, 2022 07:30AM New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
Jun 14, 2022 07:30AM The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
Jun 14, 2022 07:30AM The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
Jun 6, 2022 07:31AM Biogen (BIIB) and Alectos Announce License and Collaboration Agreement for AL01811
Jun 6, 2022 07:30AM Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Jun 6, 2022 07:30AM Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Jun 6, 2022 07:30AM Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Jun 3, 2022 08:00AM Biogen (BIIB) and Bio-Thera Report Positive Phase 3 Data for Tocilizumab Biosimilar Candidate
Jun 3, 2022 08:00AM Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
Jun 3, 2022 08:00AM Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
Jun 3, 2022 05:53AM Biogen (BIIB) Reports New 12-Month Tofersen Data Shows Clinically Meaningful Benefit in People With SOD1-ALS
Jun 3, 2022 05:20AM New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
Jun 3, 2022 05:20AM New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
Jun 2, 2022 08:01AM Biogen (BIIB) and Samsung Bioepis’ BYOOVIZ Launches in the US
Jun 2, 2022 08:00AM Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States
Jun 2, 2022 08:00AM Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States
Jun 1, 2022 06:30AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
Jun 1, 2022 06:30AM Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
View More Recent Stories View Older Stories